Skip to content

Clofazimine Effect on Cutaneous Leishmaniasis

Evaluation of Clofazimine Effect in Treatment of Cutaneous Leishmaniasis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT138710251543N1
Enrollment
24
Registered
2009-05-08
Start date
2007-09-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous Leishmaniasis. Cutaneous Leishmaniasis

Interventions

Clofazimine capsule,50-100mg/day ,orally for 3 weeks.
Treatment - Drugs
Clofazimine capsule,50-100mg/day ,orally for 3 weeks

Sponsors

Fars University of Medical Sciences and Health Services
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 139 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age more than 12 y/o, duration of disease less than 2month, no anti-leishmania (Glucantim, Rifampin, Azithromycin) treatment since 1 month prior to study, Exclusion criteria: Lesion on face and joint, pregnancy, lactation, severe diseases including hepatic, renal and cardiac diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Complete healing with re-epithelialization of cutaneous lesion. Timepoint: 3 week. Method of measurement: Physical examination and change of score, including: erythema, induration, ulceration and size of lesions.

Secondary

MeasureTime frame
Adverse effect. Timepoint: 3 weeks. Method of measurement: Physical examination and medical history.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Jaber Mazandarani

Fars University of Medical sciences and Health Services

jmaz@sums.ac.ir+98 71 1231 9049

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026